Deals: Page 3

  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    Sanofi to buy Inhibrx in deal worth up to $2.2B

    The acquisition will give Sanofi an experimental drug for alpha-1 antitrypsin deficiency, while the rest of Inhibrx's assets will be spun into a new company.

    By • Jan. 23, 2024
  • A prescription drug carton with information for the biosimilar medicine Cimerli is pictured against a white background.
    Image attribution tooltip
    Courtesy of Coherus Biosciences
    Image attribution tooltip

    Coherus sells Lucentis biosimilar to Sandoz for $170M

    The divestment, which includes sales and reimbursement staff, is part of Coherus’ plan to shift resources toward its R&D work in oncology.

    By • Jan. 22, 2024
  • Explore the Trendline➔
    Image attribution tooltip
    Brian Tucker / BioPharma Dive
    Image attribution tooltip
    Trendline

    Biotech dealmaking

    Acquisitions of biotech companies have picked up in recent quarters, suggesting depressed valuations may be facilitating deal conversations. Read this trendline for a look at the factors impacting M&A. 

    By BioPharma Dive staff
  • A conceptual illustration of neural activity in a brain.
    Image attribution tooltip
    nopparit via Getty Images
    Image attribution tooltip

    Karuna, Cerevel might be just the start of psychiatry drug M&A

    New details of the proposed buyouts show there were multiple interested buyers, which, according to analysts, could set the stage for more dealmaking.

    By • Jan. 22, 2024
  • Image attribution tooltip
    Warren Little via Getty Images
    Image attribution tooltip

    GSK to buy asthma drug startup Aiolos for $1B

    Aiolos, which raised a Series A round three months ago, is developing an antibody that shares a target with Amgen and AstraZeneca’s Tezspire.

    By • Jan. 9, 2024
  • The Merck & Co. sign at the company's building in Summit, New Jersey.
    Image attribution tooltip
    Kena Betancur via Getty Images
    Image attribution tooltip

    Merck pays $680M for struggling cancer biotech Harpoon

    The acquisition will build out Merck’s pipeline of immunotherapies as its top-seller Keytruda nears the end of U.S. market exclusivity.

    By • Jan. 8, 2024
  • Signs for Johnson & Johnson are seen on company offices in California.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J to acquire ADC drug developer Ambrx for $2B

    The proposed takeout follows a spate of dealmaking around antibody-drug conjugates, targeted cancer medicines that have lured AbbVie, Pfizer, Merck and Gilead.

    By • Jan. 8, 2024
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    Bristol Myers to acquire brain drug developer Karuna for $14B

    The deal would hand Bristol Myers, which is reprioritizing neuroscience research, an experimental treatment for schizophrenia that analysts think could become a blockbuster product.

    By , • Updated Dec. 22, 2023
  • Signs for Johnson & Johnson are seen on company offices in California.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J bets bigger on MeiraGTx’s eye gene therapy

    Ahead of a Phase 3 readout that could come next year, the pharma is paying $130 million in upfront and near-term cash for rights to the retinitis pigmentosa treatment that it didn’t already own.

    By • Dec. 21, 2023
  • The Federal Trade Commission's building sign.
    Image attribution tooltip
    Gromit702 via Getty Images
    Image attribution tooltip

    FTC, DOJ finalize merger guidelines that could impede healthcare deals

    The new guidelines may give regulators more ammunition to go after vertical and cross-market M&A that has historically been more difficult to challenge.

    By Rebecca Pifer • Dec. 19, 2023
  • A concept illustration of malignant cells, colored purple and red
    Image attribution tooltip
    koto_feja via Getty Images
    Image attribution tooltip

    Point radiopharma drug results disappoint in prostate cancer study

    While the study met its goal, the drug’s benefit was less than analysts had predicted, an outcome that could hasten a planned takeover by Eli Lilly.

    By • Dec. 18, 2023
  • The Federal Trade Commission headquarters is pictured in Washington, D.C. The agency's proposed noncompete ban may face legal challenges on several grounds.
    Image attribution tooltip
    RiverNorthPhotography via Getty Images
    Image attribution tooltip

    FTC, in unusual move, leads Sanofi to terminate a drug research deal

    Just before clearing Pfizer’s buyout of Seagen, the regulator threatened to block Sanofi’s licensing deal with Maze Therapeutics, a challenge the biotech called ‘‘unprecedented.”

    By • Dec. 12, 2023
  • Corporate logos are seen outside on May 15, 2006, in Macclesfield, England.
    Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    AstraZeneca to acquire vaccine maker Icosavax for up to $1.1B

    The deal signals the pharma company’s continuing interest in vaccine development and hands it a combination shot aimed at two respiratory viruses. 

    By • Dec. 12, 2023
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    Bristol Myers pays SystImmune $800M and adds to pharma’s ‘ADC’ deal spree

    The lucrative alliance, potentially worth more than $8 billion, continues a run of dealmaking for a class of cancer drugs that’s surged in popularity in recent years. 

    By • Dec. 12, 2023
  • A stylized stock chart is superimposed over a picture of U.S. dollars.
    Image attribution tooltip
    Maximusnd via Getty Images
    Image attribution tooltip

    Spyre Therapeutics raises $180 million to advance anti-inflammatory drugs

    The private placement funding will help Spyre develop its drug pipeline, which includes a TL1A-targeting therapy for inflammatory bowel disease.

    By • Dec. 8, 2023
  • Brain scans are seen in a stock image
    Image attribution tooltip
    sudok1 via Getty Images
    Image attribution tooltip

    AbbVie to buy Cerevel in $8.7B bet on brain drugs

    The deal hands AbbVie a portfolio of psychiatric medicines that originated within Pfizer, among them a closely watched schizophrenia treatment that’s in late-stage testing.

    By , • Updated Dec. 6, 2023
  • A Roche logo is seen on the side of a building.
    Image attribution tooltip
    Courtesy of Roche
    Image attribution tooltip
    Obesity drugs

    Roche joins obesity drug chase with $2.7B deal for startup Carmot

    The acquisition of Carmot, which had been planning an IPO, will hand Roche three weight loss medicines in early clinical testing.

    By • Dec. 4, 2023
  • A stylized stock chart is superimposed over a picture of U.S. dollars.
    Image attribution tooltip
    Maximusnd via Getty Images
    Image attribution tooltip

    Concentra, on the hunt for deals, bids for LianBio

    The Tang Capital-controlled company is bidding for LianBio shortly after making takeover offers for Rain Oncology and Theseus Pharmaceuticals.

    By • Dec. 1, 2023
  • An AbbVie sign is seen on the outside of a building in California.
    Image attribution tooltip
    Courtesy of AbbVie
    Image attribution tooltip

    AbbVie joins ADC dealmaking with $10B ImmunoGen buyout

    The acquisition of ImmunoGen gives AbbVie an approved medicine for ovarian cancer, and continues a pharma spending spree on antibody-drug conjugates.

    By • Nov. 30, 2023
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    Bristol Myers pours $100M into RNA drugs for cardiovascular diseases

    Tuesday’s deal signals the pharmaceutical giant's confidence in Avidity Biosciences and its so-called antibody oligonucleotide conjugates.

    By • Nov. 28, 2023
  • A wall showing a Merck & Co. logo in Kenilworth, New Jersey
    Image attribution tooltip
    Courtesy of Merck & Co.
    Image attribution tooltip

    Merck to buy private biotech Caraway in neuroscience deal

    In a deal worth up to $610 million, Merck will gain a pipeline of neuroscience and rare disease programs from a startup it previously backed.

    By • Nov. 21, 2023
  • Two test tubes pour different-colored liquids into a beaker in an illustration representative of biopharma mergers.
    Image attribution tooltip
    Elizabeth Regan / Industry Dive
    Image attribution tooltip

    Homology enters reverse merger with Q32 Bio

    The deal, which will result in a combined company operating under Q32's name, comes months after Homology laid off much of its staff.

    By • Nov. 16, 2023
  • A sign showing Gilead's logo
    Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    Gilead expands Arcellx cancer cell therapy deal

    The deal gives Gilead an estimated 13% ownership in Arcellx and extends the company’s cash runway into 2027.

    By • Nov. 15, 2023
  • An illustration of T cells attacking a cancer cell
    Image attribution tooltip
    Peddalanka Ramesh Babu via Getty Images
    Image attribution tooltip

    Novartis licenses Legend cell therapy for lung cancer

    With the deal, the Swiss pharma is exploring a tumor target, DLL3, that’s thwarted past drugmaker efforts to attack it.

    By • Nov. 13, 2023
  • Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip
    Obesity drugs

    AstraZeneca stays in GLP-1 drug race with new deal

    AstraZeneca is paying $185 million upfront to gain access to an experimental GLP-1 drug from China-based biotech Eccogene.

    By • Nov. 9, 2023
  • Scientists at Orum Therapeutics observing the physical appearance of an experiment.
    Image attribution tooltip
    Permission granted by Orum Therapeutics
    Image attribution tooltip

    Bristol Myers pays $100M for a different kind of ADC

    A deal with Orum Therapeutics gives the large pharma access to a blood and bone marrow cancer drug that's ready to enter clinical testing.

    By • Nov. 6, 2023